Biomerica (BMRA) Stock Price

Biomerica Price

NASDAQ·CLOSED
1.84
​
Market closed

Revenue at Biomerica has contracted by 1.3% per year over the past 19 years to 4.45 M USD. Earnings per share have grown at 0.1% per year over the last 6 years. For Biomerica, the net margin of -84.8% is down versus -24.0% a few years ago.

Biomerica stock price

Access this data via the Eulerpool API

Biomerica business model & stock analysis

Biomerica, Inc. engages in the development, manufacture, and marketing of medical diagnostic products designed for the early detection and monitoring of chronic diseases and medical conditions. The company is headquartered in Irvine, California and currently employs 84 full-time employees. The medical diagnostic products are sold in two markets: clinical laboratories and point of care. The diagnostic test kits are used to analyze blood, urine, or fecal specimens from patients in the diagnosis of various diseases and other medical complications, by measuring or detecting the existence and/or level of specific bacteria, hormones, antibodies, antigens or other substances, which may exist in a patient’s body, stools, or blood, often in extremely small concentrations. Biomerica has developed a diagnostic guided therapy that is designed to allow physicians to identify patient-specific foods, that when removed from the diet, may alleviate or improve an individual's symptoms of Irritable Bowel Syndrome (IBS). This product is called InFoods IBS.

Frequently asked questions about Biomerica

7 analysts currently rate the Biomerica stock: 6 recommend buying, 1 holding and 0 selling.

Converted at the current exchange rate, the Biomerica share trades at 1.64 EUR (1.84 USD).

The Biomerica share (BMRA) is listed on 1 stock exchanges, including: NASDAQ (BMRA).

The revenue of Biomerica is 4.45 M USD. This figure is based on current financial data and reflects the company's business performance.

The profit of Biomerica is -3.78 M USD. The net profit reflects the company's profitability after deducting all expenses.

The price-to-earnings ratio (P/E) of Biomerica is currently -1.50. The P/E ratio compares the current share price to the earnings per share and helps investors assess the valuation of the Biomerica stock.

The price-to-sales ratio (P/S) of Biomerica is currently 1.27. The P/S ratio compares the market capitalization to the annual revenue and serves as a valuation metric for the Biomerica stock.

The Eulerpool Quality Score for Biomerica is 2/10.

The ISIN of Biomerica is US09061H4065. The ISIN (International Securities Identification Number) is a globally unique identifier for securities.

The WKN of Biomerica is 866251. The WKN (Wertpapierkennnummer) is a six-digit German security identification number.

The ticker of Biomerica is BMRA. The ticker symbol is used to trade Biomerica shares on the stock exchange.

Fair ValueTerminal
1.62 USD
Over-/UndervaluationTerminal
Fairly valued
Sector
Industry
Health Care Equipment & Supplies
Number of shares
Employees
Revenue per Employee
82,462.96 USD
Revenue growth Ø5 years
EBIT growth Ø5 years
Net Income growth Ø5 years
Currency
USD
Initial public offering
Mar 17, 1980
ISIN
US09061H4065
Cusip
09061H307
Sedol
2618520
Market capitalization
5.56 M USDMicro Cap
52-Week Range
PEG
—
P/E ratio
P/Ee
—
P/S
P/Se
—
EV/EBIT
—
P/B Ratio
2.11
ROE (Return on Equity)
ROA (Return on Assets)
ROCE (Return on Capital Employed)
ROIC (Return on Invested Capital)
-75.30 %
Last updated Oct 14, 2026, 5:23 PM

All fundamentals and in-depth analysis of Biomerica

Our stock analysis for Biomerica stock includes important financial indicators such as revenue, profit, P/E ratio, P/S ratio, EBIT, as well as information on dividends. We also assess aspects such as stocks, market capitalization, debt, equity, and liabilities of Biomerica. If you are looking for more detailed information on these topics, we offer comprehensive analyses on our subpages.